Breaking News, Collaborations & Alliances

Portola Pharma Expands Clinical Collaboration with Daiichi Sankyo

Deal worth up to $25 million to develop andexanet alfa in Germany

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Portola Pharmaceuticals has expanded its existing clinical collaboration agreement with Daiichi Sankyo to develop AndexXa (andexanet alfa) as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor. AndexXa is currently under EMA review for reversal of Factor Xa inhibition in patients experiencing a life-threatening or uncontrolled bleed and for patients requiring urgent or emergency surgery. As part of the updated agreement, Portola will expand the ongoing ANNEXA-4 study in bleeding pati...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters